Zydus Lifesciences has significantly expanded its semaglutide market presence through strategic partnerships with leading pharmaceutical companies. The company has now formalized comprehensive co-marketing agreements with both Lupin Limited and Torrent Pharmaceuticals Limited to maximize patient reach through diverse distribution networks and brand portfolios across India's diabetes and weight management treatment sectors.

Enhanced Multi-Partner Strategy

Zydus has implemented a comprehensive multi-partner approach for semaglutide commercialization, establishing agreements with Lupin Limited and most recently with Torrent Pharma on March 18, 2026. These partnerships create extensive market coverage, leveraging each partner's unique strengths and distribution capabilities to enhance patient access across different market segments.

Comprehensive Brand Portfolio Distribution

The multi-partner strategy establishes distinct brand portfolios across all collaborating companies. Under the Torrent agreement, Zydus will manufacture and supply the product while Torrent Pharma receives semi-exclusive rights to co-market in India. As part of the agreement, Torrent Pharma will pay an upfront licensing fee to Zydus.

Innovation and Patient-Centric Approach

Zydus has developed an innovative formulation of Semaglutide Injection (15 mg/3 ml) in a prefilled cartridge administered using a reusable patient-friendly pen device. The formulation enables delivery of all strengths for both indications through a single device platform, designed to enhance patient convenience, improve treatment adherence, and support better long-term compliance.

Therapeutic Applications and Market Access

The semaglutide injection addresses critical therapeutic needs across India's healthcare market. The product serves adults with insufficiently controlled type 2 diabetes mellitus as monotherapy when metformin is inappropriate, or in combination with other diabetes medications. Additionally, it functions as adjunct therapy for chronic weight management in adults with BMI of 30.00 kg/m² or greater, or 27.00 kg/m² or greater with weight-related comorbid conditions including hypertension, type 2 diabetes, or dyslipidemia.

Through these strategic partnerships, Zydus combines strong product development and manufacturing capabilities with partners' deep market expertise, significantly expanding patient access to advanced GLP-1 therapies for metabolic disorders across India's diverse healthcare landscape.

Source: Company/INE010B01027/9a41d337-6456-45d6-b12b-0b2a302117c9.pdf

Sentynl Therapeutics Inc., a wholly-owned subsidiary of Zydus Lifesciences Limited , has announced a strategic licensing agreement with PRG S&T, a Korean rare disease specialist, to acquire rights to investigational drug candidate Progerinin (SLC-D011) for treating Hutchinson-Gilford Progeria Syndrome. The agreement marks a significant expansion of Sentynl's rare disease portfolio, adding a second potential therapy for this ultra-rare genetic disorder.

Licensing Agreement Details

Under the terms of the agreement, Sentynl will collaborate with PRG S&T to advance clinical development of Progerinin, which has received orphan drug designation from the United States Food and Drug Administration. The company will acquire full rights to the molecule upon meeting certain milestones, with the program currently finalizing a Phase 2A clinical trial.

About Progerinin and Its Mechanism

Progerinin represents an investigational, orally active small-molecule drug designed to treat Hutchinson-Gilford Progeria Syndrome, a rare genetic disorder characterized by accelerated aging in children. The disease stems from mutations in the LMNA gene, which cause accumulation of progerin, an abnormal form of the lamin A protein that disrupts nuclear structure and leads to premature cellular aging.

The drug candidate works by inhibiting the interaction and harmful effects of progerin within cells, thereby improving nuclear integrity and reducing cellular damage. In mouse models of HGPS, progerinin demonstrated encouraging outcomes, increasing lifespan by 8–10 weeks and improving body weight in treated subjects compared to controls.

Clinical Trial Results in Animal Models

Leadership Perspectives

Dr. Sharvil P. Patel, Managing Director of Zydus Lifesciences Limited, emphasized the acquisition's importance in growing their HGPS therapy portfolio. "Supporting patients in living healthy, fulfilled lives is core to what we do, and the agreement with PRG S&T directly furthers this mission by advancing orphan therapies for patients and families impacted by rare diseases," he stated.

Matt Heck, CEO of Sentynl, highlighted the commitment to translating research progress into real therapies. "This agreement, which will add Progerinin to our progeria portfolio, represents our commitment to translating that progress into another real therapy for children and families who need them," Heck commented.

Disease Background and Current Treatment Landscape

Hutchinson-Gilford Progeria Syndrome affects children with severe manifestations including failure to thrive, scleroderma-like skin, global lipodystrophy, alopecia, joint contractures, and accelerated atherosclerosis. Children with HGPS commonly die of heart disease by an average age of 14.50 years. Currently, Zokinvy® (lonafarnib) remains the only approved treatment for HGPS and certain processing-deficient Progeroid Laminopathies in the U.S., European Union, Great Britain, Israel, and Japan.

The Progeria Research Foundation, which funded foundational research leading to Progerinin's development, expressed support for the licensing agreement. Dr. Leslie Gordon, Medical Director at the foundation, noted their mission to find treatments and cure for Progeria, expressing gratitude for the collaborative efforts to improve patient lives.